Epcoritamab Monotherapy Provides Deep and Durable Responses Including Minimal Residual Disease (MRD) Negativity: Novel Subgroup Analyses in Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
暂无分享,去创建一个
T. Phillips | P. Lugtenburg | M. Hutchings | C. Cheah | C. Thieblemont | H. Ghesquières | W. Jurczak | T. Feldman | D. Soong | Meng‐Yu Chen | M. Poon | D. Cunningham | R. Gasiorowski | M. Clausen | D. Lewis | M. Sacchi | M. V. D. van der Poel | Tae Min Kim | Christopher Chiu | Y. Do | Mariana Cota Stirner | N. Kilavuz | B. Elliot